In a filing, Boston Scientific Corp revealed its Officer ARTHUR C BUTCHER acquired Company’s shares for reported $1.81 million on Aug 01 ’25. In the deal valued at $104.63 per share,17,313 shares were bought.
Then, JOSEPH M FITZGERALD bought 50,000 shares, generating $5,231,665 in total proceeds.
Before that, FUJIMORI YOSHIAKI sold 2,901 shares. Boston Scientific Corp shares valued at $310,378 were divested by the Director at a price of $106.99 per share. As a result of the transaction, FUJIMORI YOSHIAKI now holds 2,081 shares, worth roughly $0.22 million.
Leerink Partners initiated its Boston Scientific Corp [BSX] rating to an Outperform in a research note published on June 16, 2025; the price target was $118. A number of analysts have revised their coverage, including Needham’s analysts, who increased its forecast for the stock in mid April from “a Hold” to “a Buy”. Deutsche Bank also remained covering BSX and has increased its forecast on January 10, 2025 with a “Buy” recommendation from previously “Hold” rating. Needham revised its rating on October 18, 2024. It rated BSX as “a Hold” which previously was an “a Buy”.
Price Performance Review of BSX
On Friday, Boston Scientific Corp [NYSE:BSX] saw its stock jump 0.47% to $105.41. Over the last five days, the stock has lost -0.69%. Boston Scientific Corp shares have risen nearly 42.39% since the year began. Nevertheless, the stocks have risen 18.01% over the past one year. While a 52-week high of $108.94 was reached on 07/23/25, a 52-week low of $71.88 was recorded on 04/07/25.
Levels Of Support And Resistance For BSX Stock
The 24-hour chart illustrates a support level at 104.18, which if violated will result in even more drops to 102.95. On the upside, there is a resistance level at 106.52. A further resistance level may holdings at 107.64.
How much short interest is there in Boston Scientific Corp?
A steep rise in short interest was recorded in Boston Scientific Corp stocks on 2025-07-15, growing by 2.08 million shares to a total of 19.57 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 17.49 million shares. There was a rise of 10.61%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 30, 2024 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $90 price target.
